MiMedx
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-02-28
- Employees
- 895
- Market Cap
- -
- Website
- http://www.mimedx.com
- Introduction
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
Clinical Trials
35
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials
Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs
- Conditions
- Diabetic Foot UlcerDiabetic FootFoot Ulcer Due to Type 2 Diabetes MellitusFoot Ulcer, DiabeticFoot Ulcer
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- MiMedx Group, Inc.
- Target Recruit Count
- 170
- Registration Number
- NCT06600724
- Locations
- 🇺🇸
SerenaGroup - Monroeville, Monroeville, Pennsylvania, United States
Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds
- Conditions
- Venous Leg UlcerDiabetic Foot Ulcer
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- MiMedx Group, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06236750
- Locations
- 🇯🇵
Kobe University Hospital, Kobe-shi, Hyogo, Japan
🇯🇵Saitame Medical University Hospital, Iruma-gun, Saitama, Japan
🇯🇵Juntendo University Hospital, Bunkyō-Ku, Tokyo, Japan
Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis
- Conditions
- Knee Osteoarthritis
- Interventions
- Biological: Micronized DHACM 40 mgBiological: Micronized DHACM 100 mgDrug: Saline
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- MiMedx Group, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT05796765
- Locations
- 🇺🇸
Horizon Clinical Research, La Mesa, California, United States
🇺🇸AppleMed Research Group, LLC, Miami, Florida, United States
🇺🇸Health and Life Research Institute, LLC, Miami, Florida, United States
A Single Center, Prospective, Case Series of the Treatment of Pressure Ulcers and Decubitus Ulcers.
- Conditions
- Pressure Ulcer
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- MiMedx Group, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT03529578
- Locations
- 🇺🇸
Infectious Disease Specialists of Atlanta, PC, Decatur, Georgia, United States
Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee
- Conditions
- Knee Osteoarthritis
- Interventions
- Drug: SalineBiological: Micronized dHACM
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- MiMedx Group, Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT03485157
- Locations
- 🇺🇸
Central Research Associates, Inc, Birmingham, Alabama, United States
🇺🇸Fiel Family and Sports Medicine, Tempe, Arizona, United States
🇺🇸Horizon Clinical Research, La Mesa, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
MediWound Initiates Phase III Trial of EscharEx for Venous Leg Ulcers
MediWound has commenced a Phase III clinical trial (VALUE) to evaluate EscharEx for the treatment of venous leg ulcers (VLUs).